Medication Adherence and Coping Strategies in Patients with Rheumatoid Arthritis: A Cross-Sectional Study
Table 1
Participant characteristics and medication adherence.
N (% of total) N=120 (100%)
Medication adherent (% within variable) N=63 (52.5%)
Not completely medication adherent (% within variable) N=57 (47.5%)
p-values
Sex
Female
99 (82.5)
57 (57.6)
42 (42.4)
0.016
Male
21 (17.5)
6 (28.6)
15 (71.4)
Age
< 45 years
29 (24.2)
8 (27.6)
21(72.4)
0.008
45 – 65 years
65 (54.2)
39 (60.0)
26 (40.0)
> 65 years
26 (21.7)
16 (61.5)
10 (38.5)
Marital status
Single
16(13.3)
5 (31.3)
11 (68.8)
0.101
Married
69 (57.5)
35 (50.7)
34 (49.3)
Divorced/living separated
24 (20.0)
17 (70.8)
7 (29.7)
Widowed
11 (9.2)
6 (54.5)
5 (45.5)
Educational level
Compulsory/lower secondary
31 (25.8)
16 (51.6)
15 (48.4)
0.785
Secondary school/apprenticeship
68 (56.7)
34 (50.0)
34 (50.0)
Higher education
9 (7.5)
6 (66.7)
3 (33.3)
Other
12 (10.0)
7 (58.3)
5 (41.7)
Monthly net income
< 1000€ (1120$)
23 (19.2)
14 (60.9)
9 (39.1)
0.168
1001–2000€ (1121 -2240$)
68 (56.7)
38 (55.9)
30 (44.1)
2001–3000€ (2241-3360$)
20 (16.7)
6 (30.0)
14 (70.0)
> 3000€ (>3361$)
9 (7.5)
5 (55.6)
4 (44.4)
Disease duration
>10years
35 (29.2)
12 (34.4)
23 (65.7)
0.048
5-10 years
40 (33.3)
25 (62.5)
15 (37.5)
1-4 years
37 (30.8)
20 (54.1)
17 (45.9)
<1year
8 (6.7)
6 (75.0)
2 (25.0)
RA treatment
sDMARDs
77 (64.2)
42 (54.5)
35 (45.5)
0.246
bDMARDs
8 (6.7)
2 (25)
6 (75)
DMRAD + Biologic
30 (25)
15 (50)
15 (50)
Corticosteroids
5 (4.2)
4 (80)
1 (20)
Number of other medications
No other medications
34 (28.3)
16 (47.1)
18 (52.9)
0.120
1–2 other medications
45 (37.5)
28 (62.2)
17 (29.8)
3-4 other medications
19 (37.5)
6 (31.6)
13 (68.4)
>4 other medications
22 (18.3)
13 (59.1)
9 (40.9)
Descriptive statistic of demographic and clinical variable distribution, medication adherence, and their association with demographic and clinical variables. Values are absolute numbers (and percent of total or percent within variable). means significantly different from expected value in post hoc testing. sDMARDs: synthetic disease-modifying anti-rheumatic drugs; bDMARDs: biologic disease-modifying anti-rheumatic drugs.
